228 related articles for article (PubMed ID: 9650201)
1. [Treatment of lymphoma in the aged].
Gómez H; Colomer R
Med Clin (Barc); 1998 May; 110(15):574-5. PubMed ID: 9650201
[No Abstract] [Full Text] [Related]
2. Clinical investigations in aggressive non-Hodgkin lymphoma.
Jonathan F
Clin Adv Hematol Oncol; 2008 Sep; 6(9):7-8. PubMed ID: 18998259
[No Abstract] [Full Text] [Related]
3. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
[TBL] [Abstract][Full Text] [Related]
4. Initial chemotherapy with an age-adjusted CHOP-schedule in non-Hodgkin lymphomas with unfavorable prognosis. A study of the I.G.C.I.
Heinz R; Pawlicki M; Losonczy H; Varbiro M; Benedek S; Konopka L; Krc I; Brugiatelli M
Haematologica; 1986; 71(6):473-9. PubMed ID: 3104156
[No Abstract] [Full Text] [Related]
5. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
Seymour JF; Pro B; Fuller LM; Manning JT; Hagemeister FB; Romaguera J; Rodriguez MA; Ha CS; Smith TL; Ayala A; Hess M; Cox JD; Cabanillas F; McLaughlin P
J Clin Oncol; 2003 Jun; 21(11):2115-22. PubMed ID: 12775737
[TBL] [Abstract][Full Text] [Related]
7. [ABP therapy in advanced non-Hodgkin's lymphoma resistant to VCP therapy].
Kuraishi Y; Ozeki H; Takasaki N; Mashizu N; Nagamine D; Usui N; Yamazaki H; Nakamura T; Aiba K; Yokoyama K
Rinsho Ketsueki; 1984 Sep; 25(9):1427-32. PubMed ID: 6084069
[No Abstract] [Full Text] [Related]
8. [Clinical and therapeutic aspects of non-Hodgkin lymphoma with primary digestive localization].
Stoica I; Gociu M; Moţoiu I; Coliţă D; Berceanu S
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1984; 36(1):11-8. PubMed ID: 6203154
[No Abstract] [Full Text] [Related]
9. [Clinical characteristics and treatment of midline nasal and nasal type NK/T cell lymphoma].
Yong W; Zheng W; Zhang Y
Zhonghua Yi Xue Za Zhi; 2001 Jul; 81(13):773-5. PubMed ID: 11798962
[TBL] [Abstract][Full Text] [Related]
10. Essential thrombocythemia after treatment of non-Hodgkin's lymphoma.
Maciel JF; de Lourdes Chauffaille M; Inaoka RJ; Colleoni GW; Yamamoto M
Leuk Res; 2007 Nov; 31(11):1593-5. PubMed ID: 17324461
[No Abstract] [Full Text] [Related]
11. [Treatment of non-Hodgkin malignant lymphomas].
Gociu M; Coliţă D; Leahu S; Ciocoiu A; Berceanu S
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1984; 36(1):1-10. PubMed ID: 6145200
[No Abstract] [Full Text] [Related]
12. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage.
Lee KW; Kim DY; Yun T; Kim DW; Kim TY; Yoon SS; Heo DS; Bang YJ; Park S; Kim BK; Kim NK
Cancer; 2003 Dec; 98(12):2651-6. PubMed ID: 14669285
[TBL] [Abstract][Full Text] [Related]
13. [Non-Hodgkin's primitive lymphoma of the testis: long-term prognosis associated with treatment combining systemic and intrathecal chemotherapy].
Sénéchal C; Saint F; Petit T; Petit J
Prog Urol; 2009 Mar; 19(3):209-14. PubMed ID: 19268261
[TBL] [Abstract][Full Text] [Related]
14. CHOP versus CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
Alliot C
J Clin Oncol; 2005 Jul; 23(21):4797-9; author reply 4799-800. PubMed ID: 16034060
[No Abstract] [Full Text] [Related]
15. [Survival of patients with aggressive non-hodgkin's lymphoma: no difference between first line treatment in a prospective randomised phase III clinical trial and first line treatment according to routine clinical practice].
van Agthoven M; Wittebol S; Budel LM; Uyl-de Groot CA; Kramer MH
Ned Tijdschr Geneeskd; 2004 Jan; 148(2):88-93. PubMed ID: 14753131
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
Spina M; Simonelli C; Tirelli U
J Clin Oncol; 2007 Feb; 25(6):e7. PubMed ID: 17308261
[No Abstract] [Full Text] [Related]
17. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
Sawka CA; Shepherd FA; Franssen E; Brandwein J; Dotten DA; Routy JP; Walker IR; St-Louis J; Taylor M; Arts K; Crump M; Foote M
Biotechnol Annu Rev; 2005; 11():381-9. PubMed ID: 16216784
[TBL] [Abstract][Full Text] [Related]
18. Impressive response to temsirolimus in a patient with chemotherapy refractory diffuse large B-cell non-Hodgkin's lymphoma.
Kiewe P; Thiel E
Ann Hematol; 2011 Jan; 90(1):109-10. PubMed ID: 20387065
[No Abstract] [Full Text] [Related]
19. Plasma glutathione S-Transferase P1-1 as a prognostic factor in patients with advanced non-Hodgkin's lymphoma (stages III and IV).
Katahira T; Takayama T; Miyanishi K; Hayashi T; Ikeda T; Takahashi Y; Takimoto R; Matsunaga T; Kato J; Niitsu Y
Clin Cancer Res; 2004 Dec; 10(23):7934-40. PubMed ID: 15585627
[TBL] [Abstract][Full Text] [Related]
20. Therapy-associated genetic aberrations in patients treated for non-Hodgkin lymphoma.
Basecke J; Podleschny M; Becker A; Seiffert E; Schwiers I; Schwiers R; Haase D; Glass B; Schmitz N; Trumper L; Griesinger F
Br J Haematol; 2008 Apr; 141(1):52-9. PubMed ID: 18324966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
